Objective To explore the therapeutic effects of dupilumab and abaxitinib on atopic dermatitis(AD) in adults.

Methods A total of 140 AD patients were selected for the study, and divided into the control group (n=70) and observation group(n=70) according to the random number table method. The control group was treated with abaxitinib alone, while the observation group was treated with dupilumab alone. Both groups were treated for 3 months. The skin conditions eczema area and severity index (EASI), dermatology life quality index (DLQI) and pruritus number rating scale (P-NRS) and serological indicators interferon-γ (INF-γ), immunoglobulin E(IgE), interleukin-13 (IL-13), eosinophils (EOS), superoxide dismutase (SOD) and malondialdehyde (MDA) between two groups before and after treatment were compared. The occurrence of adverse reactions after treatment bewteen two groups was compared.

Results In the study, 4 cases were lost to follow-up in the control group, and 66 cases were eventually included, while 3 cases were lost to follow-up in the observation group, and 67 cases were eventually included. Compared with the control group, the levels of EASI, DLQI, P-NRS, IgE, IL-13, EOS and MDA significantly decreased (P < 0.01), the levels of INF-γ and DSO significantly increased (P < 0.01), and the incidence of adverse reactions significantly reduced in the observation group after treatment (P < 0.05).

Conclusions Dupilumab has a superior therapeutic effect in adult AD, can significantly improve the skin condition and inflammatory response of patients, and has high safety.